Recently, a research group in China has conducted a phase I clinical trial (NCT06010472) to evaluate the safety and efficacy of CD19-targeted CAR-NK cells (KN5501) in patients with moderate to severe refractory SLE. The gene discussed is CD19; the disease is systemic lupus erythematosus.